Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 9
- Registration Number
- NCT00998036
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 236
- Registration Number
- NCT00980460
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2012-07-10
- Target Recruit Count
- 22
- Registration Number
- NCT00979966
- Locations
- 🇩🇪
Vivantes Klinikum am Urban, Berlin, Germany
🇩🇪Charité - Campus Virchow Klinikum, Berlin, Germany
🇩🇪Charité - Mitte, Berlin, Germany
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Conditions
- Endometrial Clear Cell AdenocarcinomaRecurrent Uterine Corpus CancerStage IIIA Uterine Corpus Cancer AJCC v7Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaStage IVA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Endometrial Serous AdenocarcinomaStage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 349
- Registration Number
- NCT00977574
- Locations
- 🇺🇸
Henry Ford Health Warren Hospital, Warren, Michigan, United States
🇺🇸Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 37
- Registration Number
- NCT00942747
- Locations
- 🇩🇪
Neurology, Knappschaftskrankenhaus Bochum, Bochum University, Bochum, Germany
🇩🇪Hematology, Klinikum Frankfurt/Oder, Frankfurt an der Oder, Germany
🇩🇪Klinikum Grosshadern, University Hospital Munich, Munich, Germany
Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
- Conditions
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 9
- Registration Number
- NCT00926107
- Locations
- 🇬🇷
"Papageorgiou" General Hospital, Dept. of Medical Oncology, Thessaloniki, Greece
🇬🇷Chania General Hospital, Oncology Dept., Chania, Greece
🇬🇷Metropolitan Hospital, 2nd Dept. of Medical Oncology, Pireaus, Greece
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT00921310
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
- Conditions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT00909831
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Duke University
- Target Recruit Count
- 11
- Registration Number
- NCT00887640
- Locations
- 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00880282
- Locations
- 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.